Across TCGA pan-cancer cohorts, LINC01620 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC01620 data layer compared with 14 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher LINC01620 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01620 expression acts as an unfavorable survival marker.
KIRP and CESC are the cancer types where LINC01620 Mutation most reproducibly stratifies survival.